Adial Pharmaceuticals Inc ADIL.OQ ADIL.O is expected to show no change in quarterly revenue when it reports results on November 12 (estimated) for the period ending January 1 0001
LSEG's mean analyst estimate for Adial Pharmaceuticals Inc is for a loss of 44 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Adial Pharmaceuticals Inc is 7.50, above its last closing price of $1.07.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.53 | -0.53 | -0.59 | Missed | -10.3 |
Mar. 31 2024 | -0.33 | -0.33 | -0.62 | Missed | -87.9 |
Jan. 1 0001 | -0.89 | -0.76 | -1.35 | Missed | -77.6 |
Sep. 30 2023 | -1.13 | -1.13 | -1.18 | Missed | -4 |
Jun. 30 2023 | -1.46 | -1.50 | 0.96 | Beat | 164 |
Jan. 1 0001 | -3.50 | -3.50 | -2.75 | Beat | 21.4 |
Jan. 1 0001 | -3.75 | -3.75 | -2.75 | Beat | 26.7 |
Sep. 30 2022 | -4.75 | -4.50 | -3.00 | Beat | 33.3 |
This summary was machine generated November 8 at 15:48 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments